The Ministry of Health has given the green light to bivalent vaccines for all over 12 as a fourth dose. Ok to the quita dose to the immunosuppressed.
–
–
Turn on notifications to receive updates on
–
–
With a circular issued yesterday, the Ministry of Health, the Italian Medicines Agency and the Istituto Superiore di Sanità have given the ok to the fourth dose of the anti Covid vaccine – with the new bivalent drugs – for all over 12. Not only that: the fifth dose has also been approved for immunosuppressed (for which the primary course was three doses and they have already received the fourth).
“Following the authorization by EMA and AIFA of the original / BA.4-5 bivalent formulation of the Comirnaty vaccine, two formulations are now available as part of the anti-SARS-CoV-2 / COVID-19 vaccination campaign bivalents of m-RNA vaccines (original / omicron BA.1 by Spikevax and Comirnaty, and original / BA.4-5 by Comirnaty). of preferential use of one of the different bivalent vaccines available today, believing that all of them can expand the protection against different variants and can help maintain optimal protection against the COVID-19 disease “, explains the circular, adding that” the recommendations on use of the original / omicron BA.1 formulation are therefore also extended to the original / BA.4-5 formulation, without any distinction “.
Who are the bivalent mRna vaccines recommended for?
Specifically, the use of bivalent m-RNA vaccine formulations is recommended as a priority:
Covid Lazio, bulletin of Saturday 24 September: 1,966 new cases and 3 deaths, 945 infections in Rome
–
–
- as a second booster dose in favor of all persons aged ≥ 60 years, of the people with high frailty motivated by concomitant / pre-existing pathologies aged ≥ 12 years (Annex 1), of health workers, guests and operators of residential facilities and pregnant women, in the manner and timing provided for the same;
- as a second booster dose, upon evaluation and specialist clinical judgment, to subjects with marked impairment of the immune response, for causes related to the underlying disease or pharmacological treatments and to subjects undergoing haematopoietic or solid organ transplantation (Annex 2), who have already received a primary course of three doses (standard primary course plus additional dose at least 28 days after the last dose) and a subsequent first booster dose, at least 120 days after the last dose;
- as the first booster dose, in the manner and timing provided for the same, in favor of subjects aged ≥ 12 years who have not yet received it, regardless of the vaccine used to complete the primary course.
–
